YIH
TELO icon

Y-Intercept (HK)’s Telomir Pharmaceuticals TELO Stock Holding History

Y-Intercept (HK)’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-64,423
Closed -$80.5K – 2131
2025
Q2 		$80.5K Buy
+64,423
New +$149K ﹤0.01% 1546

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Y-Intercept (HK)'s TELO Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 64,423 shares — an estimated $80.5K sold.

Y-Intercept (HK) first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $80.5K in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 64,423 Telomir Pharmaceuticals shares in Q3 2025, an estimated $80.5K.
  • Y-Intercept (HK) first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Telomir Pharmaceuticals position peaked at $80.5K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.